Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data.
Toribio-García I, Olivares-Hernández A, Miramontes-González JP, Domínguez LP, Martín García A, Eiros Bachiller R, Figuero-Pérez L, Garijo Martínez M, Roldán Ruiz J, Bellido Hernández L, Fonseca-Sánchez E, Luis Sánchez P, Del Barco-Morillo E. Toribio-García I, et al. Among authors: del barco morillo e. Cancers (Basel). 2023 Aug 28;15(17):4293. doi: 10.3390/cancers15174293. Cancers (Basel). 2023. PMID: 37686569 Free PMC article.
Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.
Olivares-Hernández A, Del Barco Morillo E, Parra Pérez C, Miramontes-González JP, Figuero-Pérez L, Martín-Gómez T, Escala-Cornejo R, Bellido Hernández L, González Sarmiento R, Cruz-Hernández JJ, Ludeña de la Cruz MD. Olivares-Hernández A, et al. Biomedicines. 2022 Feb 2;10(2):360. doi: 10.3390/biomedicines10020360. Biomedicines. 2022. PMID: 35203569 Free PMC article.
Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy.
Olivares-Hernández A, Del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, Martín-Gómez T, Escala-Cornejo R, Vidal-Tocino R, Hernández LB, Sarmiento RG, Ludeña de la Cruz MD, Cruz-Hernández JJ, Pérez CP. Olivares-Hernández A, et al. Front Biosci (Landmark Ed). 2022 Mar 8;27(3):88. doi: 10.31083/j.fbl2703088. Front Biosci (Landmark Ed). 2022. PMID: 35345320 Free article.
The Impact of Liquid Biopsies Positive for EGFR Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients.
Roldan Ruiz J, Fuentes Gago MG, Chinchilla Tabora LM, Gonzalez Morais I, Sayagues JM, Abad Hernández M, Cordovilla Pérez MR, Ludeña de la Cruz MD, Del Barco Morillo E, Rodriguez Gonzalez M. Roldan Ruiz J, et al. Diagnostics (Basel). 2023 Jul 12;13(14):2347. doi: 10.3390/diagnostics13142347. Diagnostics (Basel). 2023. PMID: 37510091 Free PMC article.
Efficacy and safety of PARP inhibitor in non-small cell lung cancer: a systematic review with meta-analysis.
Olivares-Hernández A, Roldán-Ruiz J, Miramontes-González JP, Toribio-García I, García-Hernández JL, Posado-Domínguez L, Bellido-Hernández L, Cruz-Hernández JJ, Fonseca-Sánchez E, Del Barco-Morillo E. Olivares-Hernández A, et al. Among authors: del barco morillo e. Chin Clin Oncol. 2023 Dec;12(6):62. doi: 10.21037/cco-23-58. Chin Clin Oncol. 2023. PMID: 38195073 Free article.
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Among authors: del barco morillo e. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, Ortega AL, Bernabé R, Guirado M, Massutí B, Del Barco-Morillo E, Bosch-Barrera J, Camps C, Carroll R, Rault C, Chaib C, Penrod J, Vo L, Ralphs E, Daumont MJ. Provencio M, et al. Among authors: del barco morillo e. Transl Lung Cancer Res. 2023 Oct 31;12(10):2113-2128. doi: 10.21037/tlcr-23-176. Epub 2023 Oct 27. Transl Lung Cancer Res. 2023. PMID: 38025806 Free PMC article.
Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study.
Candal-Pedreira C, Ruano-Ravina A, Calvo de Juan V, Cobo M, Trigo JM, Carcereny E, Cucurull M, López Castro R, Solís García E, Sánchez-Gastaldo A, Massutí B, Rodríguez-Abreu D, Estival A, Guirado Risueño M, Pamiés Ramón M, García Campelo R, Alonso-Jáudenes G, Camps C, Del Barco Morillo E, González Ojea C, Dómine M, Sanchez-Hernandez A, Bosch-Barrera J, Sala González MÁ, Provencio M. Candal-Pedreira C, et al. Among authors: del barco morillo e. ERJ Open Res. 2023 Dec 4;9(6):00468-2023. doi: 10.1183/23120541.00468-2023. eCollection 2023 Nov. ERJ Open Res. 2023. PMID: 38076676 Free PMC article.
21 results